Concepedia

Publication | Open Access

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

DOIFull Paper Access

21

Citations

21

References

2012

Year

Hubertus Rosery, Walleser, Ray, Bischoff, A. Vergnenègre, Hubertus Rosery, C. Chouaïd, Heigener, Javier de Castro, Marcello Tiseo,
ClinicoEconomics and Outcomes Research

Abstract

First-line erlotinib maintenance treatment is cost-effective compared with best supportive care in EGFR wild-type stable metastatic NSCLC, irrespective of the country setting.

References

YearCitations

Page 1